Research record
Overview
Compound name: Survodutide
Development code: BI 456906
Compound classification: Synthetic dual incretin peptide (GLP-1 / glucagon receptor agonist)
Brief factual description:
Survodutide is a long-acting synthetic peptide designed to simultaneously activate glucagon-like peptide-1 (GLP-1) receptors and glucagon receptors. It is being clinically investigated for obesity, metabolic dysfunction, and non-alcoholic steatohepatitis (NASH), leveraging combined appetite suppression and increased energy expenditure.
Mechanism of Action
Primary biological targets:
GLP-1 receptor and glucagon receptor
Affected systems: Metabolic, endocrine, hepatic
Core mechanisms
GLP-1 activation → reduced appetite, delayed gastric emptying
Glucagon receptor activation → increased energy expenditure and lipid oxidation
Downstream effects
Reduced caloric intake
Increased fat utilization
Improved insulin sensitivity
Decreased hepatic fat accumulation
